10x Genomics, Inc. (TXG) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
the bull case· 4
4
disclosed supplier and customer ties in SEC filings
sec filingsedgar389
managers reporting a position in thirteen f filings
13fJun 30 '26+2.97%
change in shares held by the ten largest reporting managers in the latest quarter
13fJun 30 '264
funds on file reporting a position in TXG
n-portas of Jun 30 '26the bear case· 3
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized29
managers whose positions together make up four fifths of reported value
13fJun 30 '2611 of 24
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
10x Genomics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Laboratory Analytical Instruments
High 78.71 at 4:00 am ET, low 75.57 at 2:00 pm ET.
Of the 6 companies 10x Genomics, Inc. moves with most closely, 3 also share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 3826, Laboratory Analytical Instruments, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›tall tick = annual report · 1 on record
390 managers report a position worth $4.9B between them, and 29 of them hold 80% of it.
TXG (10x Genomics, Inc.) has 2 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.